SCHEMBL4715699

SCHEMBL4715699

O=c1ccc2c(ccn2Cc2ccc(Cl)s2)n1-c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
CYP19A1 P11511 3/20 0.34
MAPK8 P45983 2/20 0.33
MAPK9 P45984 2/20 0.33
PGR P06401 1/20 0.33
HRH2 P25021 2/20 0.32
OPRM1 P35372 1/20 0.32
BRD4 O60885 1/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ADORA2B P29275 1/20 0.31
GSK3A P49840 1/20 0.31
GSK3B P49841 1/20 0.31
F10 P00742 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6533739 0.88 SLC6A2 (0.33) SLC6A2SLC6A4SLC6A3CYP19A1MEN1
SCHEMBL4713845 0.81 BRD4 (0.46) MAPK8MAPK9PGRBRD4MEN1
SCHEMBL4714110 0.79 LMNA (0.44) MAPK8MAPK9BRD4MEN1LMNA
SCHEMBL4715635 0.78 POLB (0.52) OPRM1BRD4MEN1LMNAKMT2A
SCHEMBL5124227 0.75 SMN1; SMN2 (0.43) BRD4LMNAL3MBTL1
SCHEMBL4715873 0.75 TP53 (0.46) BRD4MEN1LMNAKMT2A
SCHEMBL5113137 0.75 HTR6 (0.44) BRD4LMNA
SCHEMBL4715863 0.75 CYP3A4 (0.46) PGRMEN1KMT2AL3MBTL1
SCHEMBL4716315 0.75 ALDH1A1 (0.47) MAPK8MAPK9LMNA
SCHEMBL4711879 0.74 MEN1 (0.41) MAPK8MAPK9MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US claimed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US claimed
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 SLC6A2 4821/4885SLC6A4 4668/4885SLC6A3 4727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.